Inactive Instrument

Catalyst Biosciences Share Price

CBIO

US14888D2080

Delayed Nasdaq 16:01:31 11/09/2026 BST			5-day change	1st Jan Change
6.815 ^USD	+1.11%		+5.36%	-11.14%

16/06/25	Crescent Biopharma Completes Merger With GlycoMimetics	MT
30/10/23	Catalyst Biosciences, Inc.(NasdaqCM:CBIO) dropped from NASDAQ Composite Index	CI

Latest news : Catalyst Biosciences

16/06/25	Crescent Biopharma Completes Merger With GlycoMimetics	MT
30/10/23	Catalyst Biosciences, Inc.(NasdaqCM:CBIO) dropped from NASDAQ Composite Index	CI
29/10/23	Beijing Continent Pharmaceutical Co., Ltd. completed the acquisition of Catalyst Biosciences, Inc. in a reverse merger transaction.	CI
29/10/23	Catalyst Biosciences, Inc. announced that it has received $4.999815 million in funding from GNI USA, Inc.	CI
26/10/23	Catalyst Biosciences, Inc. announced that it expects to receive $4.999815 million in funding from GNI USA, Inc.	CI
26/10/23	Catalyst Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
29/08/23	Catalyst Biosciences, Inc. has Changed its Name to Gyre Therapeutics, Inc	CI
14/08/23	Catalyst Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
25/07/23	Catalyst Biosciences Files Registration Statement on Behalf of Selling Stockholders	MT
15/05/23	Catalyst Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
30/03/23	Catalyst Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
29/03/23	Catalyst Biosciences, Inc. Auditor Raises 'Going Concern' Doubt	CI
01/03/23	GC Biopharma Takes Over Catalyst Biosciences' Orphan Hematology Disorder Treatment Candidates	MT

More news

Analysts' recommendations : Catalyst Biosciences

15/11/21	Piper Sandler Adjusts Price Target on Catalyst Biosciences to $4 From $16, Reiterates Overweight Rating	MT
15/11/21	Raymond James Downgrades Catalyst Biosciences to Market Perform From Outperform	MT
15/11/21	JonesTrading Downgrades Catalyst Biosciences to Hold From Buy	MT
10/02/21	Catalyst Biosciences : Piper Sandler Starts Catalyst Biosciences at Overweight With $15 Price Target	MT
04/02/21	Catalyst Biosciences : Raymond James Adjusts Price Target on Catalyst Biosciences to $18 From $20, Keeps Outperform Rating	MT

More recommendations

Press Releases : Catalyst Biosciences

11/05/24	Catalyst Biosciences : Investor presentation 556.6 KB	PU
09/05/24	Catalyst Biosciences : Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - Form 8-K	PU
08/05/24	Catalyst Biosciences : Notification of Conclusion of License Agreement by Gyre Pharmaceuticals Co - Form 8-K	PU
03/05/24	Catalyst Biosciences : Investor presentation 556.8 KB	PU
02/05/24	Catalyst Biosciences : Investor presentation 556.2 KB	PU

More press releases

Catalyst Biosciences, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of Hydronidone for the treatment of nonalcoholic steatohepatitis (NASH), a severe form of nonalcoholic fatty liver disease in the United States. Hydronidone is being evaluated for the treatment of liver fibrosis associated with a spectrum of chronic liver diseases. A Phase 1 clinical trial of Hydronidone has been completed in the United States and generated pharmacokinetic (PK), safety and tolerability data of single and multiple ascending doses of Hydronidone in United States healthy subjects. Hydronidone is a structural analogue of the approved anti-fibrotic (pulmonary fibrosis) drug pirfenidone. Hydronidone has been shown to inhibit both p38y kinase activity and TGF-b1- induced excessive collagen synthesis in vitro in hepatic stellate cells (HSCs), which are recognized as critical events in the development and progression of fibrosis in the liver.

Employees

Sector

More about the company